[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1989

Positive Fluorescent Treponemal Antibody Absorption Test in Cerebrospinal Fluid of Nonsyphilitic Persons Infected With Human Immunodeficiency Virus

Author Affiliations

Rosemarie Bitta

Universitäts-Hautklinik (Charité) Schumannstraße 20/21 1040 Berlin, German Democratic Republic

Arch Dermatol. 1989;125(12):1712-1713. doi:10.1001/archderm.1989.01670240112029
Abstract

To the Editor.—  The fluorescent treponemal antibody absorption (FTA-ABS) test is widely regarded as sensitive, outstanding, and specific for antitreponemal antibodies. Three weeks after infection, antitreponemal antibodies can be demonstrated in the serum by this test. So-called nonspecific results are rare and are associated with autoimmune diseases, diabetes mellitus, liver cirrhosis, and pregnancy.1-4False-positive results account for 6% to 10% of positive FTA-ABS test results.5-7 The occurrence of nonspecific syphilis test results in cerebrospinal fluid is estimated to be extraordinarily rare.8 However, there is a report of positive FTA-ABS test results in the cerebrospinal fluid of a patient suffering from spinal ependymoma, whereas other tests for syphilis yielded negative results.9In our investigation of cerebrospinal fluids from patients infected with human immunodeficiency virus, we performed the FTA-ABS, VDRL, and Treponema pallidum hemagglutination tests. Because the FTA-ABS test on cerebrospinal fluid is not recognized as a standard

First Page Preview View Large
First page PDF preview
First page PDF preview
×